Condition: Acute Lymphocytic Leukemia · Acute Myeloid Leukemia · Ambiguous Lineage Leukemia or Lymphoma · Sponsor: University of Oklahoma
This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.
This description comes directly from the study's public registry record.
Heme Onc Lead Nurse · 1-405-271-8777 · SCC-IIT-Office@ouhsc.edu
Always discuss trial participation with your own doctor first.
| Children's National Health System | Washington D.C., District of Columbia, United States | Withdrawn |
| Emory University | Atlanta, Georgia, United States | Not Yet Recruiting |
| University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03633955